No Detail Found!

Doctoral study program of medical science, faculty of medicine, universitas airlangga, indonesia. 2 department of dermatology and venereology, faculty of medicine, universitas airlangga, indonesia.

Author(s)
Menul Ayu Umborowati Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Indonesia.;Department of Dermatology and Venereology, Faculty of Medicine, Universitas Airlangga, Indonesia
Made Putri Hendaria Department of Dermatology and Venereology, Faculty of Medicine,Universitas Airlangga,Indonesia
Sylvia Anggraeni Department of Dermatology and Venereology, Faculty of Medicine,Universitas Airlangga,Indonesia
Irmadita Citrashanty Department of Dermatology and Venereology, Faculty of Medicine,Universitas Airlangga,Indonesia
Damayanti Department of Dermatology and Venereology, Faculty of Medicine,Universitas Airlangga,Indonesia
Afif Nurul Hidayati Department of Dermatology and Venereology, Faculty of Medicine,Universitas Airlangga,Indonesia
Anang Endaryanto Department of Child Health, Faculty of Medicine,Universitas Airlangga,Indonesia
Ingrid S Surono Food Technology Department Faculty of Engineering, Bina Nusantara University,Jakarta,Indonesia
Cita Rosita Sigit Prakoeswa Department of Dermatology and Venereology, Faculty of Medicine,Universitas Airlangga,Indonesia
Abstract
Background Psoriasis is an autoimmune disease manifested as chronic, recurrent thick red scaly plaques. Cyclosporine and methotrexate have been used as therapy for severe psoriasis since decades. This study aims to evaluate the clinical outcome of methotrexate and cyclosporine as treatment for severe psoriasis. Methods A three-year retrospective analysis was undertaken to examine the medical records of hospitalized patients with severe psoriasis. This study evaluated outcomes such as psoriasis area and severity index (PASI) and length of hospital stay (LOS). Results Twenty-six patients were included in the study. Mean PASI reduction was 42.8% (± 24.64), with greater reduction in cyclosporine group (mean 54.88±12.73%) than that in methotrexate group (mean 43.22±24.4%). Patients in cyclosporine group stayed longer (18.83±9.39 days) than patients in methotrexate group (11.65±5.91 days). Conclusion Methotrexate and cyclosporine treatment are effective for severe psoriasis. However, the hospital stays for patients receiving cyclosporine treatment might be longer.
Publication Details
Page(s) 3-8
DOI DOI not available
Published Journal: Journal of Pakistan Association of Dermatologists, Volume: 33, Issue: 1, Year: 2023

Request the full text from PASTIC

Keywords
Cyclosporine, evaluation, Medicine, Methotrexate, Psoriasis, Psoriasis
0

Citations

0

Downloads

106

Views